92 results
6-K
EX-99.2
AUTL
Autolus Therapeutics plc
7 Nov 19
Index to Condensed Consolidated Financial Statements
4:28pm
of repayment of the grant is determined to be remote, then the grant is recognized as grant income.
Operating Expenses
Research and Development Expenses …
Research and development expenses consist of costs incurred in connection with the research and development of our product candidates, which are partially
6-K
EX-99.2
AUTL
Autolus Therapeutics plc
6 May 21
Index to Condensed Consolidated Financial Statements
4:05pm
research grants used to perform specific research and development activities. We recognize grant income over the period in which we recognize the related … , and no factor is determinate. We consider all relevant factors.
Operating Expenses
Research and Development Expenses
Research and development
8-K
AUTL
Autolus Therapeutics plc
21 Mar 24
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
4:21pm
Report or Completed Interim Review.
(a) As a company that carries out extensive research and development activities, Autolus Therapeutics plc … (the “Company”) benefits from the U.K. research and development tax credit regime under the scheme for small or medium-sized enterprises (“SMEs”). Under
6-K
EX-99.1
AUTL
Autolus Therapeutics plc
8 Aug 19
Index to Condensed Consolidated Financial Statements
4:36pm
Operating expenses:
Research and development
General and administrative
Total operating expenses, net
Other income (expense):
Interest income
Other … additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization
6-K
EX-99.1
n9px3h
7 Nov 19
Index to Condensed Consolidated Financial Statements
4:28pm
6-K
EX-99.2
6745wtxr
2 Nov 23
Index to Condensed Consolidated Financial Statements
4:26pm
6-K
EX-99.2
53fgvaw6s8 m6m
5 Nov 20
Index to Condensed Consolidated Financial Statements
4:03pm
6-K
EX-99.2
6vqjcvkrwi
6 Aug 20
Current report (foreign)
4:06pm
6-K
EX-99.2
7ykfd vpo1
4 Aug 22
Index to Condensed Consolidated Financial Statements
4:06pm
6-K
EX-99.2
3grh18i8w203uktf5x
3 Aug 23
Index to Condensed Consolidated Financial Statements
4:32pm
6-K
EX-99.2
8ruxspydwwvctw2t6dl
8 Aug 19
Index to Condensed Consolidated Financial Statements
4:36pm
6-K
EX-99.2
8eww9ce 5h
5 May 22
Index to Condensed Consolidated Financial Statements
12:00am
6-K
EX-99.2
bxh 9alvzteoexqjdp
3 Nov 21
Index to Condensed Consolidated Financial Statements
4:05pm
6-K
EX-99.2
yfsh9li5mhk
14 May 19
Index to Condensed Consolidated Financial Statements
4:32pm
6-K
EX-99.2
rzf4z
4 May 23
Index to Condensed Consolidated Financial Statements
4:04pm
6-K
EX-99.2
h2chjl 8z
3 Nov 22
Index to Condensed Consolidated Financial Statements
10:31am
6-K/A
EX-99.2
hj2b gwbmemse52a
21 Nov 22
Current report (foreign) (amended)
4:03pm
6-K
EX-99.2
ixw28a7m591jwy63g
5 Aug 21
Index to Condensed Consolidated Financial Statements
4:04pm
6-K
EX-99.2
r4xoz
7 May 20
Index to Condensed Consolidated Financial Statements
12:00am